Comparison of orally administered cannabis extract and delta-9- tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: A multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group

Journal of Clinical Oncology

Volumn 24, Issue 21, 2006, Pages 3394-3400

  Strasser, Florian ^a   Luftner, Diana ^a   Possinger, Kurt ^a   Ernst, Gernot ^a   Ruhstaller, Thomas ^a   Meissner, Winfried ^a   Ko, You Dschun ^a   Schnelle, Martin ^a   Reif, Marcus ^a   Cerny, Thomas ^a  

^a Kantonsspital St Gallen Division of Oncology Haematology   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANNABIS; DRONABINOL; PLACEBO; APPETITE STIMULANT; PLANT EXTRACT; TETRAHYDROCANNABINOL;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ANEMIA; ANOREXIA; APPETITE; ARTICLE; CACHEXIA; CANCER CHEMOTHERAPY; CANCER RELATED ANOREXIA CACHEXIA SYNDROME; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG FATALITY; DRUG FEVER; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HUMAN; INCREASED APPETITE; MAJOR CLINICAL STUDY; MALE; MOOD; MULTICENTER STUDY; NAUSEA; PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SEX DIFFERENCE; TUMOR GROWTH; VERTIGO; VISUAL ANALOG SCALE; VOMITING; WEIGHT REDUCTION; GERMANY; METHODOLOGY; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION; PHYTOTHERAPY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANOREXIA; APPETITE; APPETITE STIMULANTS; CACHEXIA; CANNABIS; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PHYTOTHERAPY; PLANT EXTRACTS; QUALITY OF LIFE; TETRAHYDROCANNABINOL; TREATMENT OUTCOME;

EID: 33746793870     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.1847     Document Type: Article

References (49)

1. MacDonald N: Is there evidence for earlier intervention in cancer-associated weight loss? J Support Oncol 1:279-286, 2003
2. Strasser F, Bruera ED: Update on anorexia/cachexia. Hematol Oncol Clin North Am 16:589-617, 2002
3. Cota D, Marsicano G, Lutz B, et al: Endogenous cannabinoid system as a modulator of food intake. Int J Obes Relat Metab Disord 27:289-301, 2003
4. Di Marzo V, Goparaju SK, Wang L, et al: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410:822-825, 2001
5. Kirkham TC, Williams CM, Fezza F, et al: Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 136:550-557, 2002
6. Fride E, Ginzburg Y, Breuer A, et al: Critical role of the endogenous cannabinoid system in mouse pup suckling and growth. Eur J Pharmacol 419:207-214, 2001
7. Grotenhermen F: Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 42:327-360, 2003
8. Tramer MR, Carroll D, Campbell FA, et al: Cannabinoids for control of chemotherapy induced nausea and vomiting: Quantitative systematic review. BMJ 323:16-21, 2001
9. Sacerdote P, Martucci C, Vaccani A, et al: The nonpsychoactive component of marijuana cannabidiol modulates Chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J Neuroimmunol 159:97-105, 2005
10. Nahas GG: Hashish in Islam 9th to 18th century. Bull N Y Acad Med 58:814-831, 1982
11. Abel EL: Effects of marijuana on the solution of anagrams, memory and appetite. Nature 231:260-261, 1971
12. Foltin RW, Fishman MW, Brady JV: Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav 25:577-582, 1986
13. Foltin RW, Fischman MW, Byrne MF: Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite 11:1-14, 1988
14. Beal JE, Olson R, Laubenstein L, et al: Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 10:89-97, 1995
15. Zajicek J, Fox P, Sanders H, et al: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet 362:1517-1526, 2003
16. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al: Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled, crossover study. Mult Scler 10:417-424, 2004
17. Killestein J, Hoogervorst ELJ, Reif M, et al: Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 58:1404-1407, 2002
18. Berman JS, Symonds C, Birch R: Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomised controlled trial. Pain 112:299-306, 2004
19. Regelson W, Butler JR, Schulz J, et al: Tetrahydrocannbinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients, in Braude MC, Szara S (eds): The Pharmacology of Marijuana: A Monograph of the National Institute of Drug Abuse. New York, NY, Raven, 1976, pp 763-776
20. Plasse TF, Gorter RW, Krasnow SH, et al: Recent clinical experience with dronabinol. Pharmacol Biochem Behav 40:695-700, 1991
21. Nelson K, Walsh D, Deeter P, et al: A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 10:14-18, 1994
22. Jatoi A, Windschitl HE, Loprinzi CL, et al: Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: A North Central Cancer Treatment Group Study. J Clin Oncol 20:567-573, 2002
23. United States Food and Drug Administration, Department of Health and Human Services: FDA Good Clinical Practice Program. http://www.fda.gov/oc/gcp/ regulations.html
24. European Union Directive 91/507/EEC: Commission Directive 91/507/EEC of 19 July 1991 modifying the Annex to Council Directive 75/318/EEC on the approximation of the laws of Member States relating to analytical, pharmacotoxicological and clinical standards and protocols in respect of the testing of medicinal products. http://europa.eu.int/smartapi/cgi/sga_doc? smartapi!celexapi!prod!CELEXnumdoc& numdoc=31991L0507&model= guichett&lg=en
25. The World Medical Association: The World Medical Association: Policy: World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. http://www.wma.net/e/policy/b3.htm
26. Chvetzoff G, Tannock IF: Placebo effects in oncology. J Natl Cancer Inst 95:19-29, 2003
27. Fayers PM, Aaronson NK, Bjordal K, et al: The EORTC QLQ-C30 Scoring Manual (ed 2). Brussels, Belgium, European Organization for Research and Treatment of Cancer, 1999
28. Ribaudo JM, Cella D, Hahn EA, et al: Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res 9:1137-1146, 2000
29. Musty RE: Individual differences as predictors of marijuana phenomenology, in Marijuana: An International Research Report. Proceedings of the Melbourne Symposium on Cannabis, 2-4 September 1987, monograph series no. 7. Canberra, Australia, Australian Government Publishing Service, 1988
30. Cancer Therapy Evaluation Program: Common Toxicity Criteria, Version 2.0. http://ctep.info.nih.gov/reporting/CTC-3test.html
31. Sloan JA, Cella D, Frost M, et al: Assessing clinical significance in measuring oncology patient quality of life: Introduction to the symposium, content overview, and definition of terms. Mayo Clin Proc 77:367-370, 2002
32. SAS Institute Inc: SAS Screen Control Language: Syntax, Version 6 (ed 1). Cary, NC, SAS Institute Inc, 1992, pp 124
33. Cerny T, Lueftner D, Possinger K, et al: Oral cannabis extract (CE) versus delta-9-tetrahydrocannabinol (THC) for patients with cancer-related anorexia (CRA): A randomized, double-blind, placebo-controlled multicenter study. Proc Am Soc Clin Oncol 22:730, 2003 (abstr 2934)
34. Bauer P, Könne K: Evaluation of experiments with adaptive interim analyses. Biometrics 50:1029-1041, 1994
35. Lehmacher W, Wassmer G: Adaptive sample size calculations in group sequential trials. Biometrics 55:1286-1290, 1999
36. Kieser M, Bauer P, Lehmacher W: Inference on multiple endpoints in clinical trials with adaptive interim analyses. Biometrical J 41:261-277, 1999
37. Lepri AC, Smith GD, Mocroft A, et al: A practical approach to adjusting for attrition bias in HIV clinical trials with serial marker responses. AIDS 12:1155-1161, 1998
38. Myers WR: Handling missing data in clinical trials: An overview. Drug Info J 34:525-533, 2000
39. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH E9. Statistical Principles for Clinical Trials. London, United Kingdom, European Agency for the Evaluation of Medicinal Products, 1998
40. de Jong FA, Engels FK, Mathijssen RH, et al: Medicinal cannabis in oncology practice: Still a bridge too far? J Clin Oncol 23:2886-2891, 2005
41. Hall W, Christie M, Currow D: Cannabinoids and cancer: Causation, remediation, and palliation. Lancet Oncol 6:35-42, 2005
42. Massa F, Marsicano G, Hermann H, et al: The endogenous cannabinoid system protects against colonie inflammation. J Clin Invest 113:1202-1209, 2004
43. Argiles JM, Busquets S, Lopez-Soriano FJ: Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care 6:401-406, 2003
44. Izzo AA: Cannabinoids and intestinal motility: Welcome to CB2 receptors. Br J Pharmacol 142: 1201-1202, 2004
45. Bruera E, Belzile M, Neumann C, et al: A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage 19:427-435, 2000
46. Dahele M, Fearon KC: Research methodology: Cancer cachexia syndrome. Palliat Med 18:409-417, 2004
47. Fearon KC, Von Meyenfeldt MF, Moses AG, et al: Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: A randomised double blind trial. Gut 52:1479-1486, 2003
48. Gordon JN, Trebble TM, Ellis RD, et al: Thalidomide in the treatment of cancer cachexia: A randomised placebo controlled trial. Gut 54:540-545, 2005
49. Jatoi A, Rowland K, Loprinzi CL, et al: An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: A North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol 22:2469-2476, 2004